Translartion. Region: Russians Fedetion –
Source: Moscow Government – Government of Moscow –
The pharmaceutical plant located in Zelenograd, one of the leading pharmaceutical companies in Russia, has confirmed its status as an industrial complex. The company will continue to receive tax benefits, which will allow it to further significantly reduce its financial burden. This was reported by the Deputy Mayor of Moscow for Transport and Industry Maxim Liksutov.
“Sergey Sobyanin defined the development of the pharmaceutical complex as one of the city’s key priorities. A number of projects are being implemented in the capital to strengthen the country’s medicinal sovereignty and there is a pool of comprehensive tools to support enterprises. Among them is the assignment of the status of an industrial complex, which provides for a special tax regime for companies. Thus, one of the capital’s pharmaceutical plants has confirmed the right to a special status, which will allow it to continue to receive tax benefits. Today, the enterprise produces a wide range of drugs and vaccines in accordance with international quality standards. Since the beginning of the year, the plant has produced more than 890 thousand packages of drugs, including drugs for the treatment of renal failure, hemostatic agents for local use, immunomodulators, bronchodilators and local anesthetics for the Russian and foreign markets,” said Maxim Liksutov.
For the company “Binnofarm Group” the property tax has been halved, and the rental rate has been reduced fivefold – to 0.3 percent of the cadastral value of the site. The plant uses the saved funds for its own development.
“Today, the site is undergoing final preparations for the launch of production of drugs based on monoclonal antibodies against rheumatoid arthritis and for the treatment of osteoporosis. The first batches of drugs will enter civilian circulation by the end of 2025 – beginning of 2026,” said the Minister of the Moscow Government, head of the capital’s Department of Investment and Industrial Policy
Previously, assistance from the Moscow Fund for the Support of Industry and Entrepreneurship was attracted to implement this project in the form of compensation for part of the interest on an investment loan in the amount of 1.5 billion rubles.
According to the plant’s corporate director for production activities, Anatoly Yaglenko, production will be launched in about a month. This global project required large-scale investments and the construction of new capacities at the plant from scratch. The support that the enterprise receives from the city helps reduce the tax burden.
Medicines based on monoclonal antibodies are modern medicines and can significantly improve the quality of life of patients, and their production makes a significant contribution to the fight against complex diseases.
Previously The Mayor of Moscow said on increasing the volume of drug production in January by 12.3 percent with the support of the city.
Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.
Please Note; This Information is Raw Content Directly from the Information Source. It is access to What the Source Is Stating and Does Not Reflect
https: //vv.mos.ru/nevs/ite/151478073/